Absence of association between ex vivo susceptibility to doxycycline and pftetQ and pfmdt copy numbers in Plasmodium falciparum isolates from Dakar, Senegal

Clinical Microbiology and Infection

Volumn 18, Issue 7, 2012, Pages

  Gaillard, T ^a,b   Fall, B ^c   Tall, A ^d   Wurtz, N ^a   Diatta, B ^c   Lavina, M ^a   Fall, K B ^c   Sarr, F D ^d   Baret, E ^a   Dieme Y ^c   Wade, B ^c   Bercion, R ^c   Briolant, S ^a   Pradines, B ^a,e  

^a INSTITUT DE RECHERCHE BIOMÉDICALE DES ARMÉES   (France)

^b Military Teaching Hospital Sainte Anne   (France)

^c HÔPITAL PRINCIPAL DE DAKAR   (Senegal)

^d INSTITUT PASTEUR DE DAKAR   (Senegal)

^e Centre National de Reference du Paludisme   (France)

Author keywords

Antimalarial drug; in vitro; Malaria; Plasmodium; Resistance

Indexed keywords

DOXYCYCLINE; MOLECULAR MARKER;

ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG SENSITIVITY; EX VIVO STUDY; GENE DOSAGE; HUMAN; IC 50; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; NONHUMAN; PFMDT GENE; PFTETQ GENE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENEGAL; VALIDATION PROCESS;

PLASMODIUM FALCIPARUM;

EID: 84862618397     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03889.x     Document Type: Article

References (14)

1. Société de Pathologie Infectieuse de Langue Française, Collège des Universitaires de Maladies Infectieuses et Tropicales, Société de Médecine des Armées et al. Management and prevention of imported Plasmodium falciparum malaria: recommendations for clinical practice 2007 (revision 2007 of the 1999 consensus conference). Med Mal Infect 2008; 38: 68-117.
2. World Health Organization. WHO guidelines for the treatment of malaria. WHO/HTM/MAL/2006.1108.
3. Pang L, Limsomwong N, Singharaj P. Prophylactic treatment of vivax and falciparum malaria with low-dose doxycycline. J Infect Dis 1988; 158: 1124-1127.
4. Wallace MR, Sharp TW, Smoak B et al. Malaria among United States troops in Somalia. Am J Med 1996; 100: 49-55.
5. Plowe CV, Rooper C, Barnwell JW et al. World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malaria J 2007; 6: 121.
6. Briolant S, Baragatti M, Parola P et al. Multinormal in vitro distribution model suitable for the distribution of Plasmodium falciparum chemosusceptibility to doxycycline. Antimicrob Agents Chemother 2009; 53: 688-695.
7. Briolant S, Wurtz N, Zettor A et al. Susceptibility of Plasmodium falciparum isolates to doxycycline is associated with pftetQ sequence polymorphisms and pftetQ and pfmdt copy numbers. J Infect Dis 2010; 201: 152-159.
8. Fall B, Diawara S, Sow K et al. Ex vivo susceptibility of Plasmodium falciparum isolates from Dakar, Senegal, to seven standard anti-malarial drugs. Malar J 2011; 10: 310.
9. Weiss WR, Oloo AJ, Johnson A et al. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis 1995; 171: 1569-1575.
10. Shanks GD, Roessler P, Edstein M et al. Doxycycline for malaria prophylaxis in Australian soldiers deployed to United Nations missions in Somalia and Cambodia. Mil Med 1995; 160: 443-444.
11. Shmuklarsky MJ, Boudreau EF, Pang LW et al. Failure of doxycycline as a causal prophylactic agent against Plasmodium falciparum malaria in healthy nonimmune volunteers. Ann Int Med 1994; 120: 294-299.
12. Dahl EL, Rosenthal PJ. Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrob Agents Chemother 2007; 51: 3485-3490.
13. Pradines B, Spiegel A, Rogier C et al. Antibiotics for prophylaxis of Plasmodium falciparum infections: in vitro activity of doxycycline against Senegalese isolates. Am J Trop Med Hyg 2000; 62: 82-85.
14. Pradines B, Rogier C, Fusai T et al. In vitro activities of antibiotics against Plasmodium falciparum are inhibited by iron. Antimicrob Agents Chemother 2001; 45: 1746-1750.